Show simple item record

dc.contributor.authorGafanov, R.
dc.contributor.authorPowles, T. B.
dc.contributor.authorBedke, J.
dc.contributor.authorStus, V.
dc.contributor.authorWaddell, Tom
dc.contributor.authorNosov, D.
dc.contributor.authorPouliot, F.
dc.contributor.authorSoulieres, D.
dc.contributor.authorMelichar, B.
dc.contributor.authorAzevedo, S.
dc.contributor.authorMcDermott, R. S.
dc.contributor.authorVynnychenko, I. O.
dc.contributor.authorBorchiellini, D.
dc.contributor.authorMarkus, M.
dc.contributor.authorBondarenko, I.
dc.contributor.authorLin, J.
dc.contributor.authorBurgents, J.
dc.contributor.authorMolife, L. R.
dc.contributor.authorPlimack, E. R.
dc.contributor.authorRini, B.
dc.date.accessioned2021-10-28T09:26:14Z
dc.date.available2021-10-28T09:26:14Z
dc.date.issued2021en
dc.identifier.citationGafanov R, Powles TB, Bedke J, Stus V, Waddell TS, Nosov D, et al. 669P Subsequent therapy following pembrolizumab + axitinib or sunitinib treatment for advanced renal cell carcinoma (RCC) in the phase III KEYNOTE-426 study. Vol. 32, Annals of Oncology. Elsevier BV; 2021. p. S694.en
dc.identifier.doi10.1016/j.annonc.2021.08.065en
dc.identifier.urihttp://hdl.handle.net/10541/624711
dc.description.abstractBackground:In the phase III KEYNOTE-426 study, pembrolizumab + axitinib showedsignificant improvement in OS, PFS, and ORR vs sunitinib in patients with RCC. Thisanalysis assessed subsequent treatment in patients enrolled in KEYNOTE-426.Methods:Treatment-naive patients with clear cell RCC, KPS score =70%, andmeasurable disease (RECIST v1.1) were randomly assigned 1:1 to receive pem-brolizumab 200 mg IV every 3 weeks for up to 35 doses + axitinib 5 mg orally twicedaily or sunitinib 50 mg once daily (4 weeks on/2 weeks off) until progression, toxicity,or withdrawal. Type of and time to subsequent therapy were assessed.Results:Of patients in the pembrolizumab + axitinib arm and in the sunitinib arm,81.4% (349/432) and 90.6% of patients (385/429), respectively, discontinued treat-ment; radiologic or clinical PD was the most common reason for discontinuation inboth (pembrolizumab + axitinib: 65.0% [227/349]; sunitinib: 68.1% [262/385]). Ofpatients who discontinued, 58.5% of patients (204/349) in the pembrolizumab +axitinib arm and 73.0% (281/385) in the sunitinib arm received subsequent therapy(Table). Although a similar proportion of patients in both arms received subsequenttherapy with a VEGF/VEGFR inhibitor (pembrolizumab + axitinib: 88.2% [180/204];sunitinib: 68.7% [193/281]), a greater proportion of patients in the sunitinib arm(74.4% [209/281]) received subsequent PD-1/PD-L1 inhibitor therapy than in thepembrolizumab + axitinib arm (21.6% [44/204]). Of patients in the pembrolizumab +axitinib arm and the sunitinib arm, 32.4% (66/204) and 22.8% (64/281), respectively,received other therapies.Conclusions:The superior efficacy of pembrolizumab + axitinib compared withsunitinib is observed despite the increased use of subsequent therapy in the sunitinibarm. These data continue to support the use offirst-line pembrolizumab + axitinib in patients with RCCen
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.annonc.2021.08.065en
dc.titleSubsequent therapy following pembrolizumab plus axitinib or sunitinib treatment for advanced renal cell carcinoma (RCC) in the phase III KEYNOTE-426 studyen
dc.typeOtheren
dc.contributor.departmentUrology, Russian Scientific Center of Roentgenoradiology, Moscow, Russian Federa-tion;en
dc.identifier.journalAnnals of Oncologyen
dc.description.noteen]
refterms.dateFOA2021-11-03T09:57:51Z


Files in this item

Thumbnail
Name:
AnnOncGafanov.pdf
Size:
97.71Kb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record